Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Immune Suppression
  • Lung Neoplasms
  • Pain
Type
Interventional
Phase
Phase 4
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Study plan: The hypothesis is that there is no difference in the amount of pain the patients will experience after VATS for pulmonary neoplasms. Study design and setting: The project is designed as a prospectively, double blinded, randomized, placebo controlled study comparing pain in two groups of ...

Study plan: The hypothesis is that there is no difference in the amount of pain the patients will experience after VATS for pulmonary neoplasms. Study design and setting: The project is designed as a prospectively, double blinded, randomized, placebo controlled study comparing pain in two groups of patients. Both groups of patients will: Have a epidural catheter placed. Receive a basis level of analgesics consisting of paracetamol and a nonsteroidal anti- inflammatory drug combined with a nerveblock placed intercostally during surgery. Have access to i.v. opioids as needed for any experienced pain after surgery. One group of patients will be given local anaesthetics through the epidural catheter supplemented with placebo medication orally while the other group will receive saline in the epidural catheter supplemented with opioids orally. Data collection: Data will, during hospitalization, be collected in the operating theatre, in the postoperative care unit and in the surgical ward. Six months after surgery a questionnaire will be send to the patients to do follow-up regarding residual sequelae after surgery and placement of epidural catheter. Further follow-up with questionnaire has been planned for subsequent years. As a secondary objective, in fifty-six of the patients from The SEAVATS Study, blood samples will be gathered during surgery and one hour and 24 hours after surgery, and compared with pre-operative levels. These blood samples will be analysed for immune cells (NK-cells, levels and activity) and cytokines (IL-6, IL-10, IL-12 and IFN-gamma) as indicators of immunological response to surgery. Research ethics: The project has obtained ethics approval from The Regional Scientific Ethical Committees for Southern Denmark and acceptance to perform clinical research has been granted by The Danish Health and Medicines Authority. Consent to data collection has been provided by The Danish Data Protection Agency. Before entering the project, consent will be obtained from all patients. Rigorous data security will be maintained for five years and afterwards all data will be deleted. The Study is registered with The European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) with EudraCT number 2014-000760-18 and is monitored by The Good Clinical Practice unit for Southern Denmark.

Tracking Information

NCT #
NCT02359175
Collaborators
Not Provided
Investigators
Principal Investigator: Jimmy H Holm, MD Department of Anaesthesia and Intensive Care - Odense University Hospital